IGFBP6 Protéine
Aperçu rapide pour IGFBP6 Protéine (ABIN935551)
Antigène
Voir toutes IGFBP6 ProtéinesType de proteíne
Activité biologique
Origine
Source
Pureté
-
-
Séquence
- RCPGCGQGVQ AGCPGGCVEE EDGGSPAEGC AEAEGCLRRE GQECGVYTPN CAPGLQCHPP KDDEAPLRAL LLGRGRCLPA RAPAVAEENP KESKPQAGTA RPQDVNRRDQ QRNPGTSTTP SQPNSAGVQD TEMGPCRRHL DSVLQQLQTE VYRGAQTLYV PNCDHRGFYR KRQCRSSQGQ RRGPCWCVDR MGKSLPGSPD GNGSSSCPTG SSG
-
Attributs du produit
-
Purified recombinant Human IGF BP6 protein
Expression System: Hi-5 cells
Bioactivity: Determined by its ability to inhibit IGF-II induced proliferation of human MCF-7 cells. The expected ED50 for this effect is 0.1 - 0.4 µg/mL. -
niveau d'endotoxine
- < 0.1 ng per µg (1 EU/µg).
-
-
Vous souhaitez d'autres options pour ce Protein ?
!Découvrez nos protéines personnalisées prédéfinies et nos services de protéines sur mesure !Votre projet nécessite-t-il une personnalisation supplémentaire ? Contactez-nous et découvrez nos solutions protéiques sur mesure
-
-
-
Indications d'application
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Commentaires
-
Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Buffer
- Supplied as a lyophilized powder.
-
Conseil sur la manipulation
- Avoid repeated freeze/thaw cycles.
-
Stock
- RT/-20 °C
-
-
- IGFBP6 (Insulin-Like Growth Factor Binding Protein 6 (IGFBP6))
-
Autre désignation
- IGF BP6
-
Sujet
-
IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid, and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma.
Alternative Names: IGF BP-6 protein, IBP-6 protein, IGF BP 6, IGF BP6, IGF BP 6 protein, IGF BP-6 protein, IGF BP-6 -
Poids moléculaire
- 22.6 kDa
-
Pathways
- Signalisation WNT, Myometrial Relaxation and Contraction
Antigène
-